zeltia sa (ZLIXF) Key Developments
Zeltia Announces Earnings Results for the First Half of 2015
Jul 30 15
Zeltia announced earnings results for the first half of 2015. For the period, the company reported total net revenues of EUR 84.4 million, a 7.8% increase compared with the same period of 2014. The company obtained EUR 9.5 million in EBITDA compared with EUR 22 million in the same period of 2014. The company reported EUR 3.33 million in net attributable profit compared with EUR 17.7 million in the first half of 2014, which represents an 80% profit drop.
Zeltia SA to Report Q2, 2015 Results on Jul 28, 2015
Jul 22 15
Zeltia SA announced that they will report Q2, 2015 results on Jul 28, 2015
Zeltia SA, Annual General Meeting, Jun 30, 2015
May 29 15
Zeltia SA, Annual General Meeting, Jun 30, 2015., at 11:30 Eastern Daylight. Location: Instituto Ferial de Vigo (IFEVI) site on Avenida del Aeropuerto, 772, Cotogrande -. 36318- Vigo.
Zeltia Reports Earnings Results for the First Quarter of 2015
Apr 29 15
Zeltia reported earnings results for the first quarter of 2015. For the period, the company's net profit dropped 61% to EUR 6.5 million (USD 7.1 million) compared with EUR 16.9 million in the equivalent period of 2014. Net sales in the biopharmaceutical sector amounted to EUR 21.1 million, compared with EUR 20.9 million in first-quarter 2014. The main reason for Zeltia's negative financial performance during the beginning of the year is the reduction in milestone payment under an agreement signed with Janssen in 2011 on the development of oncology product Yondelis, which for first-quarter 2015 corresponded to only USD 10 million, compared with USD 25 million in first-quarter 2014.
Zeltia SA Presents at UBS Global Healthcare Conference, May-18-2015
Apr 21 15
Zeltia SA Presents at UBS Global Healthcare Conference, May-18-2015 . Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: José-Luis Moreno, IR & Capital Markets Director.